Literature DB >> 28386661

The evolving role for re-irradiation in the management of recurrent grade 4 glioma.

Steven P Howard1, Andra Krauze2, Mike D Chan3, Christina Tsien4, Wolfgang A Tomé5.   

Abstract

Although significant gains have been realized in the management of grade 4 glioma, the majority of these patients will ultimately suffer local recurrence within the prior field of treatment. Clearly, novel local treatment strategies are required to improve patient outcomes. Concerns of toxicity have limited enthusiasm for the utilization of re-irradiation as a treatment option. However, using modern imaging technology and precision radiotherapy delivery techniques re-irradiation has proven a feasible option achieving both a palliative benefit and prolongation of survival with low toxicity rates. The evolution of re-irradiation as a treatment modality for recurrent grade 4 glioma is reviewed. In addition, potential targeted radiosensitizers to be used in conjunction with re-irradiation are also discussed.

Entities:  

Keywords:  Central nervous system; Radiosensitizers; Re-irradiation; Recurrent grade 4 glioma

Mesh：

Substances：

Year:  2017        PMID： 28386661     DOI： 10.1007/s11060-017-2392-1

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  44 in total

Review 1.  Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma.

Authors:  L C Hygino da Cruz; I Rodriguez; R C Domingues; E L Gasparetto; A G Sorensen
Journal:  AJNR Am J Neuroradiol       Date:  2011-03-10       Impact factor: 3.825

2.  Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option.

Authors:  Maya Flieger; Ute Ganswindt; Silke Birgit Schwarz; Friedrich-Wilhelm Kreth; Jörg-Christian Tonn; Christian la Fougère; Lorenz Ertl; Jennifer Linn; Ulrich Herrlinger; Claus Belka; Maximilian Niyazi
Journal:  J Neurooncol       Date:  2014-02-07       Impact factor: 4.130

3.  Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma.

Authors:  G Minniti; V Armosini; M Salvati; G Lanzetta; P Caporello; M Mei; M F Osti; R Enrici Maurizi
Journal:  J Neurooncol       Date:  2010-11-05       Impact factor: 4.130

4.  A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma.

Authors:  Wolfgang Wick; Harald Fricke; Klaus Junge; Grigory Kobyakov; Tobias Martens; Oliver Heese; Benedikt Wiestler; Maximilian G Schliesser; Andreas von Deimling; Josef Pichler; Elena Vetlova; Inga Harting; Jürgen Debus; Christian Hartmann; Claudia Kunz; Michael Platten; Martin Bendszus; Stephanie E Combs
Journal:  Clin Cancer Res       Date:  2014-10-22       Impact factor: 12.531

5.  Fractionated stereotactic radiotherapy with cis-platinum radiosensitization in the treatment of recurrent, progressive, or persistent malignant astrocytoma.

Authors:  J Glass; C L Silverman; R Axelrod; B W Corn; D W Andrews
Journal:  Am J Clin Oncol       Date:  1997-06       Impact factor: 2.339

6.  Generation and validation of a prognostic score to predict outcome after re-irradiation of recurrent glioma.

Authors:  Stephanie E Combs; Lutz Edler; Renate Rausch; Thomas Welzel; Wolfgang Wick; Jürgen Debus
Journal:  Acta Oncol       Date:  2012-06-11       Impact factor: 4.089

7.  Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution.

Authors:  Stephanie E Combs; Christoph Thilmann; Lutz Edler; Jürgen Debus; Daniela Schulz-Ertner
Journal:  J Clin Oncol       Date:  2005-12-01       Impact factor: 44.544

8.  Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial treatment option after high-dose radiotherapy?

Authors:  Emmanouil Fokas; Ulrich Wacker; Markus W Gross; Martin Henzel; Elitsa Encheva; Rita Engenhart-Cabillic
Journal:  Strahlenther Onkol       Date:  2009-04-16       Impact factor: 3.621

9.  Identification of novel radiosensitizers in a high-throughput, cell-based screen for DSB repair inhibitors.

Authors:  Alexander G Goglia; Robert Delsite; Antonio N Luz; David Shahbazian; Ahmed F Salem; Ranjini K Sundaram; Jeanne Chiaravalli; Petrus J Hendrikx; Jennifer A Wilshire; Maria Jasin; Harriet M Kluger; J Fraser Glickman; Simon N Powell; Ranjit S Bindra
Journal:  Mol Cancer Ther       Date:  2014-12-15       Impact factor: 6.009

10.  Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma.

Authors:  Dirk Vordermark; Oliver Kölbl; Klemens Ruprecht; Giles H Vince; Klaus Bratengeier; Michael Flentje
Journal:  BMC Cancer       Date:  2005-05-30       Impact factor: 4.430
View more
  4 in total

1.  Clinical outcomes of dose-escalated re-irradiation in patients with recurrent high-grade glioma.

Authors:  Corbin A Helis; Shih-Ni Prim; Christina K Cramer; Roy Strowd; Glenn J Lesser; Jaclyn J White; Stephen B Tatter; Adrian W Laxton; Christopher Whitlow; Hui-Wen Lo; Waldemar Debinski; James D Ververs; Paul J Black; Michael D Chan
Journal:  Neurooncol Pract       Date:  2022-05-02

2.  Nucleolar and spindle-associated protein 1 is a tumor grade correlated prognosis marker for glioma patients.

Authors:  Tao Zhu; Pan Xie; Yuan-Feng Gao; Ma-Sha Huang; Xi Li; Wei Zhang; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  CNS Neurosci Ther       Date:  2018-01-15       Impact factor: 5.243

3.  High-dose re-irradiation of intracranial lesions - Efficacy and safety including dosimetric analysis based on accumulated EQD2Gy dose EQD calculation.

Authors:  I Stiefel; C Schröder; S Tanadini-Lang; I Pytko; E Vu; R J Klement; M Guckenberger; N Andratschke
Journal:  Clin Transl Radiat Oncol       Date:  2021-02-04

4.  Re-irradiation for malignant glioma: Toward patient selection and defining treatment parameters for salvage.

Authors:  Colette J Shen; Megan N Kummerlowe; Kristin J Redmond; Juan Carlos Martinez-Gutierrez; Syed Muhammad Usama; Matthias Holdhoff; Stuart A Grossman; John J Laterra; Roy E Strowd; Lawrence R Kleinberg
Journal:  Adv Radiat Oncol       Date:  2018-07-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.